Table 1.
Patients’ baseline characteristics
| Groups Parameter | Men (1) n = 14 | Women (2) n = 13 | Pregnant women (3) n = 16 | |||
|---|---|---|---|---|---|---|
| Mean | % (range) | Mean | % (range) | Mean | % (range) | |
| Cauc4/other | 11/3 | 78.5/21.5 | 5/8 | 38.5/61.5 | 7/9 | 43.8/56.2 |
| Age (years) | 47.2 | (33–61) | 33.4 | (27–58) | 29.4 | (22–41) |
| Bodyweight (kg) | 76.3 | (65–87) | 58.8 | (44–84) | 70.2 | (54–87) |
| CDC status B/C3 | 3/9 | 21.4/64.3 | 7/2 | 53.8/15.4 | 5/3 | 31.3/18.8 |
| HCV-PCR positive | 1 | 7.1 | 1 | 7.7 | 3 | 18.8 |
| CD4 cell count | 280 | (15–720) | 209 | (17–610) | 333 | (116–696) |
| Viral load (log10) | 2.57 | (1.28–5.27) | 3.10 | (1.28–5.55) | 4.09 | (1.28–5.62) |
| Previous treatments | 5.0 | (0–11) | 2.9 | (0–8) | 2.6 | (0–4) |
| NNRTI-naïve | 9 | 64.3 | 7 | 53.8 | 5 | 31.3 |
| Treatment-naive | 2 | 14.3 | 4 | 30.1 | 5 | 31.3 |
| Concomitant nucleoside or nucleotide reverse transcriptase inhibitors | ||||||
| Zidovudine | 5 | 35.7 | 5 | 38.5 | 16 | 100 |
| Lamivudine | 11 | 78.6 | 12 | 92.3 | 16 | 100 |
| Tenofovir | 5 | 35.7 | 4 | 30.8 | – | – |
| Stavudine | 3 | 21.4 | 4 | 30.8 | – | – |
| Abacavir | 4 | 28.6 | 1 | 7.7 | – | – |
| Didanosine | 2 | 14.3 | 1 | 7.7 | – | – |